Tech Company Financing Transactions

Sonoma Biotherapeutics Funding Round

Sonoma Biotherapeutics, operating out of San Francisco, secured $30 million from 8VC, Alexandria Venture Investments and Arch Venture Partners.

Transaction Overview

Announced On
10/1/2020
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series A
Proceeds Purpose
The Series A financing will enable Jeff and the rest of the organization to continue their great progress.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
400 E. Jamie Ct. 250
San Francisco, CA 94080
USA
Phone
Undisclosed
Email Address
Overview
Best-in-class regulatory T cell therapy, delivering long-lasting, highly effective, curative treatments across a spectrum of autoimmune and degenerative diseases. Founded by pioneers in regulatory T cell therapy, Sonoma brings together next-generation research, development and manufacturing capabilities in cell therapy and genetic engineering.
Profile
Sonoma Biotherapeutics LinkedIn Company Profile
Social Media
Sonoma Biotherapeutics Company Twitter Account
Company News
Sonoma Biotherapeutics News
Facebook
Sonoma Biotherapeutics on Facebook
YouTube
Sonoma Biotherapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Jeffrey Bluestone
  Jeffrey Bluestone LinkedIn Profile  Jeffrey Bluestone Twitter Account  Jeffrey Bluestone News  Jeffrey Bluestone on Facebook
Chief Medical Officer
Leonard Dragone
  Leonard Dragone LinkedIn Profile  Leonard Dragone Twitter Account  Leonard Dragone News  Leonard Dragone on Facebook
Chief Scientific Officer
Fred Ramsdell
  Fred Ramsdell LinkedIn Profile  Fred Ramsdell Twitter Account  Fred Ramsdell News  Fred Ramsdell on Facebook
Vice President
James Adams
  James Adams LinkedIn Profile  James Adams Twitter Account  James Adams News  James Adams on Facebook
Vice President
Joshua Beilke
  Joshua Beilke LinkedIn Profile  Joshua Beilke Twitter Account  Joshua Beilke News  Joshua Beilke on Facebook
Vice President
Sejal Hall
  Sejal Hall LinkedIn Profile  Sejal Hall Twitter Account  Sejal Hall News  Sejal Hall on Facebook
VP - Bus. Development
Peter DiLaura
  Peter DiLaura LinkedIn Profile  Peter DiLaura Twitter Account  Peter DiLaura News  Peter DiLaura on Facebook
VP - Finance
Jillian McGuire
  Jillian McGuire LinkedIn Profile  Jillian McGuire Twitter Account  Jillian McGuire News  Jillian McGuire on Facebook
VP - Human Resources
Tamara Fountain
  Tamara Fountain LinkedIn Profile  Tamara Fountain Twitter Account  Tamara Fountain News  Tamara Fountain on Facebook
VP - Product Management
Anne-Renee Van Der Vuurst de Vries
  Anne-Renee Van Der Vuurst de Vries LinkedIn Profile  Anne-Renee Van Der Vuurst de Vries Twitter Account  Anne-Renee Van Der Vuurst de Vries News  Anne-Renee Van Der Vuurst de Vries on Facebook
VP - Product Management
Vanessa Van Voorhis
  Vanessa Van Voorhis LinkedIn Profile  Vanessa Van Voorhis Twitter Account  Vanessa Van Voorhis News  Vanessa Van Voorhis on Facebook


 

 

Browse more venture capital transactions:

Prev: 10/1/2020: BEGiN venture capital transaction
Next: 10/1/2020: Liquid Death venture capital transaction

 

Share this article

 


Where The Data Comes From

We report on funding rounds that are announced publicly. VC transactions on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary